Lan Liu, Weihao Zhang, Wei Zhao, Shuang Guo, Yaojun Wang, Xiaojun Lv, Bing Li, Haiping Wang, Enbin Xu, Quan Li, Qin Zhu, Xiao Bo Gou, Weidong Zhao, Jianqiang Guo
INTRODUCTION: Linaclotide, a guanylate cyclase C agonist that improves the symptoms of irritable bowel syndrome with predominant constipation (IBS-C), has been recently approved for IBS-C treatment. This study aimed to report real-world data on linaclotide treatment in China. METHODS: This was a prospective multicentre study of the effectiveness of linaclotide treatment in patients with IBS-C from 10 primary medical institutions. Changes in defecation, abdominal symptoms, the IBS symptom severity scale (IBS-SSS), IBS quality of life questionnaire (IBS-QOL), Zung Self-Rating Anxiety Scale and Self-Rating Depression Scale in patients were evaluated to determine the drug's clinical efficacy and safety...
2022: Therapeutic Advances in Gastroenterology